top of page

Development of the global inflammatory bowel disease visualization of epidemiology studies

Updated: Aug 19, 2023

Development of the global inflammatory bowel disease visualization of epidemiology studies in the 21st century (GIVES-21)

Joyce W Y Mak, Yang Sun, Julajak Limsrivilai, Murdani Abdullah, Jamilya Kaibullayeva, Domingo Balderramo, Beatriz Iade Vergara, Mukesh Sharma Paudel, Rupa Banerjee, Ida Hilmi, Raja Affendi Raja Ali, Shu Chen Wei, Ka Kei Ng, Mansour Altuwaijri, Paul Kelly, Jesus K Yamamoto-Furusho, Paulo Gustavo Kotze, Vineet Ahuja, Vui Heng Chong, Hang Viet Dao, Yvonne Abbey, Jessica Y L Ching , Agnes Ho , Alicia K W Chan, Charles N Bernstein, Richard B Gearry, Maria Abreu, David T Rubin, Iris Dotan, Lindsay Hracs, Gilaad G Kaplan, Siew C Ng, GIVES-21 Consortium

Publised in BMC Medical Research Methodology, May 2023



There is a rapid increase in the incidence of inflammatory bowel diseases (IBD) in newly industrialized countries, yet epidemiological data is incomplete. We herein report the methodology adopted to study the incidence of IBD in newly industrialized countries and to evaluate the effect of environmental factors including diet on IBD development.


Global IBD Visualization of Epidemiology Studies in the 21st Century (GIVES-21) is a population-based cohort of newly diagnosed persons with Crohn's disease and ulcerative colitis in Asia, Africa, and Latin America to be followed prospectively for 12 months. New cases were ascertained from multiple sources and were entered into a secured online system. Cases were confirmed using standard diagnostic criteria. In addition, endoscopy, pathology and pharmacy records from each local site were searched to ensure completeness of case capture. Validated environmental and dietary questionnaires were used to determine exposure in incident cases prior to diagnosis.


Through November 2022, 106 hospitals from 24 regions (16 Asia; 6 Latin America; 2 Africa) have joined the GIVES-21 Consortium. To date, over 290 incident cases have been reported. All patients have demographic data, clinical disease characteristics, and disease course data including healthcare utilization, medication history and environmental and dietary exposures data collected. We have established a comprehensive platform and infrastructure required to examine disease incidence, risk factors and disease course of IBD in the real-world setting.


The GIVES-21 consortium offers a unique opportunity to investigate the epidemiology of IBD and explores new clinical research questions on the association between environmental and dietary factors and IBD development in newly industrialized countries.


Recent Posts

See All


bottom of page